Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Greil

Showing results (181-190 of 483) with videos related to

Pageof 49
Sort By:
International Journal of Molecular Sciences|January 29, 2016
miR-16-5p Is a Stably-Expressed Housekeeping MicroRNA in Breast Cancer Tissues from Primary Tumors and from Metastatic SitesGabriel Rinnerthaler, Hubert Hackl, Simon Peter Gampenrieder, et al.
BMC Cancer|October 18, 2015
CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancerThomas Melchardt, Clemens Hufnagl, Teresa Magnes, et al.
BMC Cancer|August 11, 2012
Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study groupAnke Reinacher-Schick, Karsten Schulmann, Dominik P Modest, et al.
Journal of Molecular Medicine (Berlin, Germany)|February 26, 2008
Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13Olaf Merkel, Christoph Heyder, Daniela Asslaber, et al.
Oncology Letters|January 23, 2020
Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancerClemens Hufnagl, Michael Leisch, Lukas Weiss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2018
BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear TranslocationDaniela Asslaber, Nathalie Wacht, Michael Leisch, et al.
Onkologie|May 18, 2011
Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern EuropeRichard Greil, Simona Borštnar, Katarína Petráková, et al.
European Journal of Radiology|April 29, 2023
Prognostic value of [<sup>18</sup>F]FDG PET/CT on treatment response and progression-free survival of gastroesophageal cancer patients undergoing perioperative FLOT chemotherapySeyed Ali Mirshahvalad, Seyedeh Sara Seyedinia, Florian Huemer, et al.
Anticancer Research|October 7, 2017
Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3Ewald Wöll, Josef Thaler, Felix Keil, et al.
Annals of Surgery|May 15, 2019
Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE TrialFlorian Fitzal, Vesna Bjelic-Radisic, Michael Knauer, et al.
Pageof 49

Showing results (181-190 of 483) with videos related to

Sort By:
Pageof 49
International Journal of Molecular Sciences|January 29, 2016
miR-16-5p Is a Stably-Expressed Housekeeping MicroRNA in Breast Cancer Tissues from Primary Tumors and from Metastatic SitesGabriel Rinnerthaler, Hubert Hackl, Simon Peter Gampenrieder, et al.
BMC Cancer|October 18, 2015
CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancerThomas Melchardt, Clemens Hufnagl, Teresa Magnes, et al.
BMC Cancer|August 11, 2012
Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study groupAnke Reinacher-Schick, Karsten Schulmann, Dominik P Modest, et al.
Journal of Molecular Medicine (Berlin, Germany)|February 26, 2008
Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13Olaf Merkel, Christoph Heyder, Daniela Asslaber, et al.
Oncology Letters|January 23, 2020
Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancerClemens Hufnagl, Michael Leisch, Lukas Weiss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2018
BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear TranslocationDaniela Asslaber, Nathalie Wacht, Michael Leisch, et al.
Onkologie|May 18, 2011
Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern EuropeRichard Greil, Simona Borštnar, Katarína Petráková, et al.
European Journal of Radiology|April 29, 2023
Prognostic value of [<sup>18</sup>F]FDG PET/CT on treatment response and progression-free survival of gastroesophageal cancer patients undergoing perioperative FLOT chemotherapySeyed Ali Mirshahvalad, Seyedeh Sara Seyedinia, Florian Huemer, et al.
Anticancer Research|October 7, 2017
Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3Ewald Wöll, Josef Thaler, Felix Keil, et al.
Annals of Surgery|May 15, 2019
Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE TrialFlorian Fitzal, Vesna Bjelic-Radisic, Michael Knauer, et al.
Pageof 49